Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Control Release ; 314: 62-71, 2019 11 28.
Artigo em Inglês | MEDLINE | ID: mdl-31654686

RESUMO

Cystic fibrosis (CF) is a serious lung disease, commonly susceptible to Pseudomonas aeruginosa colonization. The dense mucus together with biofilm formation limit drug permeability and prevent the drug from reaching the site of action, causing treatment failure of the bacterial infection. Besides the use of antibiotics, the mucolytic agent N-acetylcysteine (NAC) is recommended to be co-administered in the treatment of CF. Although several formulations have been developed for inhalation therapy to improve the pulmonary condition in CF patients, there is still no comprehensive study on a combined multifunctional dry powder formulation of antibiotics with NAC. In this work, we developed an innovative multifunctional dry powder inhaler (DPI) formulation based on salt formation between NAC and antibiotics and characterized their solid state properties and physical stability. NAC could be spray dried together with three different antibiotics, azithromycin (Azi), tobramycin (Tobra) and ciprofloxacin (Cipro), without the use of organic solvents to form Azi/NAC, Tobra/NAC and Cipro/NAC DPI formulations. Solid-state characterization of these DPI formulations showed that they were amorphous after spray drying. Azi/NAC and Tobra/NAC form co-amorphous salt systems that were physically stable under storage at stress conditions. For particle characterization, the obtained mass median aerodynamic diameters were in a suitable range for inhalation (< 5.0µm). The multifunctional antibiotic/NAC formulations conserved or improved the antibiotic susceptibility and showed promising results regarding the inhibition of P. aeruginosa PA14 biofilm formation.


Assuntos
Acetilcisteína/administração & dosagem , Antibacterianos/administração & dosagem , Biofilmes/efeitos dos fármacos , Fibrose Cística/tratamento farmacológico , Pseudomonas aeruginosa/efeitos dos fármacos , Acetilcisteína/farmacologia , Administração por Inalação , Animais , Antibacterianos/farmacologia , Azitromicina/administração & dosagem , Azitromicina/farmacologia , Ciprofloxacina/administração & dosagem , Ciprofloxacina/farmacologia , Fibrose Cística/complicações , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Expectorantes/administração & dosagem , Expectorantes/farmacologia , Cavalos , Muco/microbiologia , Tamanho da Partícula , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/fisiologia , Tobramicina/administração & dosagem , Tobramicina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA